4.4 Review

Glucagon in type 2 diabetes: Friend or foe?

期刊

出版社

WILEY
DOI: 10.1002/dmrr.3609

关键词

cotadutide; diabetic kidney disease; dual agonists; glucagon; NAFLD; type 2 diabetes

向作者/读者索取更多资源

Hyperglucagonemia contributes to the pathogenesis of type 2 diabetes and its complications. Glucagon regulates glucose homeostasis and can affect weight, liver disease, peripheral neuropathy, and retinopathy. However, its role in diabetic nephropathy and cardiovascular system is uncertain. This review aims to summarize the current understanding and calls for further research on modulating glucagon signaling for new antidiabetic drugs.
Hyperglucagonemia is one of the 'ominous' eight factors underlying the pathogenesis of type 2 diabetes (T2D). Glucagon is a peptide hormone involved in maintaining glucose homoeostasis by increasing hepatic glucose output to counterbalance insulin action. Long neglected, the introduction of dual and triple agonists exploiting glucagon signalling pathways has rekindled the interest in this hormone beyond its classic effect on glycaemia. Glucagon can promote weight loss by regulating food intake, energy expenditure, and brown and white adipose tissue functions through mechanisms still to be fully elucidated, thus its role in T2D pathogenesis should be further investigated. Moreover, the role of glucagon in the development of T2D micro- and macro-vascular complications is elusive. Mounting evidence suggests its beneficial effect in non-alcoholic fatty liver disease, while few studies postulated its favourable role in peripheral neuropathy and retinopathy. Contrarily, glucagon receptor agonism might induce renal changes resembling diabetic nephropathy, and data concerning glucagon actions on the cardiovascular system are conflicting. This review aims to summarise the available findings on the role of glucagon in the pathogenesis of T2D and its complications. Further experimental and clinical data are warranted to better understand the implications of glucagon signalling modulation with new antidiabetic drugs.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据